Liprazide 30 Tabs (lisinopril)

$18.00

Liprazide 30 Tabs (lisinopril)

Produced in Ukraine

Free International Shipping

Description

Liprazide 30 Tabs (lisinopril)
Composition:
active ingredients: lisinopril and hydrochlorothiazide; 1 tablet of Liprazide 10 contains lisinopril (in terms of 100% anhydrous lisinopril) – 10 mg, which corresponds to lisinopril dihydrate – 10.89 mg and hydrochlorothiazide (in terms of 100% dry matter) – 12.5 mg 1 tablet of Liprazide 20 contains lisinopril (in terms of 100% anhydrous lisinopril) – 20 mg, which corresponds to lisinopril dihydrate – 21.78 mg and hydrochlorothiazide (in terms of 100% dry matter) – 12.5 mg auxiliary substances: Liprazide 10 – beckons (E 421), corn starch, magnesium stearate, iron oxide yellow (E 172), calcium hydrogen phosphate dihydrate. Liprazide 20 – beckons (E 421), corn starch, magnesium stearate, iron oxide red (E 172), calcium hydrogen phosphate dihydrate.
Indications:
Arterial hypertension, if monotherapy with hydrochlorothiazide or lisinopril does not achieve the desired reduction in blood pressure.
Contraindications:
Hypersensitivity to lisinopril, hydrochlorothiazide, other components of the drug or other ACE inhibitors hypersensitivity to sulfonamide derivatives; a history of angioedema caused by previous use of ACE inhibitors, hereditary or idiopathic angioedema (Quincke’s edema), a history of mitral or aortic stenosis, hypertrophic cardiomyopathy with severe hemodynamic disorders; acute myocardial infarction with unstable hemodynamics; cardiogenic shock severe renal failure (creatinine clearance <30 ml / min), serum creatinine level ≥ 220 μmol / L, anuria bilateral renal artery stenosis or renal artery stenosis of a single kidney condition after kidney transplantation; mechanical obstruction of the urinary tract; violation of water-salt metabolism (resistant to treatment hyperkalemia / hypokalemia, refractory hyponatremia, hypovolemia) severe forms of diabetes mellitus, severe hepatic failure, hepatic encephalopathy, primary hyperaldosteronism; exacerbation of porphyria gout; use with aliskirenvmisny drugs for patients with diabetes mellitus or with impaired renal function (GFR <60 ml / min / 1.73 m 2); the use of high-throughput membranes with polyacrylonitrile sodium-2-methylalyl sulfonate (eg AN 69) in hemodialysis; pregnant women or women planning to become pregnant
Method of administration and dosage:
The drug should be prescribed taking into account the doses of lisinopril or hydrochlorothiazide, which were used in monotherapy. The dose should be selected individually depending on the therapeutic effect. The initial recommended dose (in terms of lisinopril) is 5-10 mg / day, then the dose should be adjusted taking into account the achieved clinical effect. A stable therapeutic effect usually develops after 2-4 weeks of using the drug. The recommended maintenance dose is 20 mg once a day. The maximum daily dose (in terms of lisinopril) is 40 mg. If it is necessary to take the drug in a dose of 2.5 mg and 5 mg (in terms of lisinopril), dosage forms with the possibility of such dosage should be used.
Shelf life:
3 years. Do not use after the expiration date printed on the package.
Storage conditions:
In original packaging at a temperature not exceeding 25 ° C.